UroGen Pharma Ltd (URGN)

NASDAQ
8.42
-0.24(-2.77%)
After Hours
8.42
0.00(0.00%)
- Real-time Data
  • Volume:
    62,022
  • Day's Range:
    8.35 - 8.72
  • 52 wk Range:
    4.85 - 19.66

URGN Overview

Prev. Close
8.66
Day's Range
8.35-8.72
Revenue
57.69M
Open
8.72
52 wk Range
4.85-19.66
EPS
-5.05
Volume
62,022
Market Cap
191.48M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
153,228
P/E Ratio
-1.69
Beta
0.904
1-Year Change
-43.6%
Shares Outstanding
22,740,526
Next Earnings Date
Nov 14, 2022
What is your sentiment on UroGen Pharma?
or
Market is currently closed. Voting is open during market hours.

UroGen Pharma Ltd News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade
  • Analog Devices Earnings, Revenue Beat in Q3
    • ByInvesting.com-

    Investing.com - Analog Devices (NASDAQ:ADI) reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations. Analog Devices...

  • TJX Earnings Beat, Revenue Misses In Q2
    • ByInvesting.com-

    Investing.com - TJX (NYSE:TJX) reported on Wednesday second quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. TJX announced earnings per...

  • UroGen Pharma Tops Q2 EPS by 10c
    • ByInvesting.com-

    UroGen Pharma (URGN) reported Q2 EPS of ($1.18), $0.10 better than the analyst estimate of ($1.28). Revenue for the quarter came in at $16.6 million versus the consensus estimate...

UroGen Pharma Ltd Analysis

UroGen Pharma Ltd Company Profile

UroGen Pharma Ltd Company Profile

Employees
195

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyNeutralBuySell
Technical IndicatorsNeutralSellStrong SellStrong BuyStrong Sell
SummaryNeutralNeutralSellStrong BuyStrong Sell
  • what happend?
    0
    • good quarterly results for Q2 2020, UroGen reported a net loss of $31.3 million, or basic and diluted net loss per ordinary share of $1.44 beat 1.59 estimate
      0
      • UroGen reported a net loss of $31.3 million, or basic and diluted net loss per ordinary share of $1.44 BEAT $1.58 estimate
        0